An adenovirus type 5 (AdV5) vector encoding an envelope domain III-based tetravalent antigen elicits immune responses against all four dengue viruses in the presence of prior AdV5 immunity

Vaccine

Volumn 27, Issue 43, 2009, Pages 6011-6021

  Khanam, Saima ^a   Pilankatta, Rajendra ^a   Khanna, Navin ^a   Swaminathan, Sathyamangalam ^a  

^a INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

Adenovirus type 5; Dengue virus; Prior adenovirus immunity; Tetravalent dengue vaccine

Indexed keywords

ADENOVIRUS VECTOR; DENGUE VACCINE; GAMMA INTERFERON; INTERLEUKIN 4; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ADENOVIRUS 5; ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; BLOOD; BLOOD SAMPLING; CARBOXY TERMINAL SEQUENCE; CELL STRAIN HEK293; CELL STRAIN U937; CELLULAR IMMUNITY; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; FEMALE; HELA CELL; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; GENETIC VECTORS; HUMANS; MALE; MICE; MICE, INBRED BALB C; VIRAL ENVELOPE PROTEINS;

EID: 70349265942     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.07.073     Document Type: Article

References (75)

1. Swaminathan S., and Khanna N. Dengue: recent advances in biology and current status of translational research. Curr Mol Med 9 (2009) 152-173
2. Guha-Sapir D., and Schimmer B. Dengue fever: new paradigms for a changing epidemiology. Emerg Themes Epidemiol 2 (2005) 1
3. Halstead S. Dengue. Lancet 370 (2007) 1644-1652
4. Gubler DJ, Kuno G, Markoff L. Flaviviruses. In: Knipe DM, Howley PM, editors-in-chief. Fields virology, 5th ed. Wolters Kluwer and Lippincott Williams & Wilkins, Philadelphia;2007:1153-252.
5. Mackenzie J.S., Gubler D.J., and Petersen L.R. Emerging flaviviruses: the spread and resurgence of Japanese encephalitis, West Nile and dengue viruses. Nat Med 10 (2004) S98-S109
6. Innis B.L. Antibody responses to dengue virus infection. In: Gubler D.J., and Kuno G. (Eds). Dengue and dengue hemorrhagic fever (1997), CAB International, New York 221-243
7. Halstead S.B., Heinz F.X., Barrett A.D.T., and Roehrig J.T. Dengue virus: molecular basis of cell entry and pathogenesis. Vaccine 23 (2005) 849-856
8. Halstead S.B., and Deen J. The future of dengue vaccines. Lancet 360 (2002) 1243-1245
9. Hombach J., Barrett A.D., Cardosa M.J., Deubel V., Guzman M., Kurane I., et al. Review on flavivirus vaccine development: proceedings of a meeting jointly organized by the World Health Organization and the Thai ministry of public health. Vaccine 23 (2005) 2689-2695
10. Swaminathan S., and Khanna N. Viral vaccines for dengue: the present and the future. WHO Den Bull 27 (2003) 181-191
11. Hombach J. Vaccines against dengue: a review of current candidate vaccines at advanced development stages. Pan Am J Pub Health 21 (2007) 254-260
12. Guy B., and Almond J.W. Towards a dengue vaccine: progress to date and remaining challenges. Comp Immunol Microbiol Infect Dis 31 (2008) 239-252
13. Kanesa-Thasan N., Sun W., Kim-Ahn G., Van Albert S., Putnak J.R., King A., et al. Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers. Vaccine 19 (2001) 3179-3188
14. Edelman R., Wasserman S.S., Bodison S.A., Putnak R.J., Eckels K.H., Tang D., et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg 69 Suppl. 6 (2003) 48-60
15. Kitchener S., Nissen M., Nasveld P., Forrat R., Yoksan S., Lang J., et al. Immunogenicity and safety of two live-attenuated tetravalent dengue vaccine formulations in healthy Australian adults. Vaccine 24 (2006) 1238-1241
16. Sun W., Cunningham D., Wasserman S.S., Perry J., Putnak J.R., Eckels K.H., et al. Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-näive adults. Human Vac 5 (2009) 33-40
17. Guirakhoo F., Arroyo J., Pugachev K.V., Miller C., Zhang Z.X., Weltzin R., et al. Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol 75 (2001) 7290-7304
18. Guirakhoo F., Pugachev K., Zhang Z., Myers G., Levenbook I., Draper K., et al. Safety and efficacy of chimeric yellow fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 78 (2004) 4761-4775
19. Guirakhoo F., Kitchener S., Morrison D., Forrat R., McCarthy K., Nichols R., et al. Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™-DEN2) vaccine: phase I clinical trial for safety and immunogenicity: effect of yellow fever prior immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes. Human Vac 2 (2006) 60-67
20. Blaney Jr. J.E., Hanson C.T., Firestone C.Y., Hanley K.A., Murphy B.R., and Whitehead S.S. Genetically modified, live attenuated dengue virus type 3 vaccine candidates. Am J Trop Med Hyg 71 (2004) 811-821
21. Blaney Jr. J.E., Matro J.M., Murphy B.R., and Whitehead S.S. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in Rhesus monkeys. J Virol 79 (2005) 5516-5528
22. Suzuki R., Winkelmann E.R., and Mason P.W. Construction and characterization of a single-cycle chimeric flavivirus vaccine candidate that protects mice against lethal challenge with dengue virus type 2. J Virol 83 (2009) 1870-1880
23. Putnak J.R., Coller B.A., Voss G., Vaughn D.W., Clements D., Peters I., et al. An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model. Vaccine 23 (2005) 4442-4452
24. Simmons M., Nelson W.M., Wu S.J., and Hayes C.G. Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58 (1998) 655-662
25. Kelly E.P., Greene J.J., King A.D., and Innis B.L. Purified dengue 2 virus envelope glycoprotein aggregates produced by baculovirus are immunogenic in mice. Vaccine 18 (2000) 2549-2559
26. Konishi E., Yamaoka M., Kurane I., and Mason P.W. A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice. Vaccine 18 (2000) 1133-1139
27. Men R., Wyatt L., Tokimatsu I., Arakaki S., Shameem G., Elkins R., et al. Immunization of rhesus monkeys with a recombinant of modified vaccinia virus Ankara expressing a truncated envelope glycoprotein of dengue type 2 virus induced resistance to dengue type 2 virus challenge. Vaccine 18 (2000) 3113-3122
28. Simmons M., Murphy G.S., and Hayes C.G. Short report: antibody responses of mice immunized with a tetravalent dengue recombinant protein subunit vaccine. Am J Trop Med Hyg 65 (2001) 159-161
29. Muné M., Rodríguez R., Ramírez R., Soto Y., Sierra B., Roche R.R., et al. Carboxy-terminally truncated dengue 4 virus envelope glycoprotein expressed in Pichia pastoris induced neutralizing antibodies and resistance to dengue 4 virus challenge in mice. Arch Virol 148 (2003) 2267-2273
30. Hermida L., Rodríguez R., Lazo L., Bernardo L., Silva R., Zulueta A., et al. A fragment of the envelope protein from dengue-1 virus, fused in two different sites of the meningococcal P64k protein carrier, induces a functional immune response in mice. Biotechnol Appl Biochem 39 (2004) 107-114
31. Hermida L., Rodríguez R., Lazo L., Silva R., Zulueta A., Chinea G., et al. A dengue-2 envelope fragment inserted within the structure of the P64k meningococcal protein carrier enables a functional immune response against the virus in mice. J Virol Methods 115 (2004) 41-49
32. Mota J., Acosta M., Argotte R., Figueroa R., Méndez A., and Ramos C. Induction of protective antibodies against dengue virus by tetravalent DNA immunization of mice with domain III of the envelope protein. Vaccine 23 (2005) 3469-3476
33. Apt D., Raviprakash K., Brinkman A., Semyonov A., Yang S., Skinner C., et al. Tetravalent neutralizing antibody response against four dengue serotypes by a single chimeric dengue envelope antigen. Vaccine 24 (2006) 335-344
34. Konishi E., Kosugi S., and Imoto J.I. Dengue tetravalent DNA vaccine inducing neutralizing antibody and anamnestic responses to four serotypes in mice. Vaccine 24 (2006) 2200-2207
35. Hermida L., Bernardo L., Martín J., Alvarez M., Prado I., López C., et al. A recombinant fusion protein containing the domain III of the dengue-2 envelope protein is immunogenic and protective in nonhuman primates. Vaccine 24 (2006) 3165-3171
36. Jaiswal S., Khanna N., and Swaminathan S. Replication-defective adenoviral vaccine vector for the induction of immune responses to dengue virus type 2. J Virol 77 (2003) 12907-12913
37. Holman D.H., Wang D., Raviprakash K., Raja N.U., Luo M., Zhang J., et al. Two complex, adenovirus-based vaccines that together induce immune responses to all four dengue virus serotypes. Clin Vac Immunol 14 (2007) 182-189
38. Raviprakash K., Wang D., Ewing D., Holman D.H., Block K., Woraratanadharm J., et al. A tetravalent dengue vaccine based on a complex adenovirus vector provides significant protection in Rhesus monkeys against all four serotypes of dengue virus. J Virol 82 (2008) 6927-6934
39. Khanam S., Etemad B., Khanna N., and Swaminathan S. Induction of neutralizing antibodies specific to dengue virus serotypes 2 and 4 by a bivalent antigen composed of linked envelope domains III of these two serotypes. Am J Trop Med Hyg 74 (2006) 266-277
40. Khanam S., Khanna N., and Swaminathan S. Induction of antibodies and T cell responses by dengue virus type 2 envelope domain III encoded by plasmid and adenoviral vectors. Vaccine 24 (2006) 6513-6525
41. Khanam S., Rajendra P., Khanna N., and Swaminathan S. An adenovirus prime/plasmid boost strategy for induction of equipotent immune responses to two dengue virus serotypes. BMC Biotechnol 7 (2007) 10
42. Brandler S., Lucas-Hourani M., Moris A., Frenkiel M.P., Combredet C., Février M., et al. Pediatric measles vaccine expressing a dengue antigen induces durable serotype-specific neutralizing antibodies to dengue virus. PLoS Negl Trop Dis 1 (2007) e96
43. Chen S., Yu M., Jiang T., Deng Y., Qin C., and Qin E. Induction of tetravalent protective immunity against four dengue serotypes by the tandem domain III of the envelope protein. DNA Cell Biol 26 (2007) 361-367
44. Etemad B., Batra G., Raut R., Dahiya S., Khanam S., Swaminathan S., et al. An envelope domain III-based chimeric antigen produced in Pichia pastoris elicits neutralizing antibodies against all four dengue virus serotypes. Am J Trop Med Hyg 79 (2008) 353-363
45. Modis Y., Ogata S., Clements D., and Harrison S.C. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci USA 100 (2003) 6986-6991
46. Modis Y., Ogata S., Clements D., and Harrison S.C. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol 79 (2005) 1223-1231
47. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., et al. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3 (1997) 866-871
48. Crill W.D., and Roehrig R.T. Monoclonal antibodies that bind to domain III of dengue virus E glycoprotein are the most efficient blockers of virus adsorption to Vero cells. J Virol 75 (2001) 7769-7773
49. Hung J.J., Hsieh M.T., Young M.J., Kao C.L., King C.C., and Chang W. An external loop region of domain III of dengue virus type 2 envelope protein is involved in serotype-specific binding to mosquito but not mammalian cells. J Virol 78 (2004) 378-388
50. Kuhn R.J., Zhang W., Rossman M.G., Pletnev S.V., Corver J., Lenches E., et al. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 (2002) 717-725
51. Jaiswal S., Khanna N., and Swaminathan S. High-level expression and one-step purification of recombinant dengue virus type-2 envelope domain III protein in Escherichia coli. Protein Exp Purif 33 (2004) 80-91
52. Chin J.F.L., Chu J.J.H., and Ng M.L. The envelope glycoprotein domain III of dengue virus serotypes 1 and 2 inhibit virus entry. Microbes Infect 9 (2007) 1-6
53. Sukupolvi-Petty S., Austin S.K., Purtha W.E., Oliphant T., Nybakken G.E., Schlesinger J.J., et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 81 (2007) 12816-12826
54. Mégret F., Hugnot J.P., Falconar A., Gentry M.K., Morens D.M., Murray J.M., et al. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue envelope glycoprotein. Virology 187 (1992) 480-491
55. Gromowski G.D., and Barrett A.D.T. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366 (2007) 349-360
56. Gromowski G.D., Barrett N.D., and Barrett A.D.T. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J Virol 82 (2008) 8828-8837
57. Lin B., Parrish C.R., Murray J.M., and Wright P.J. Localization of a neutralizing epitope on the envelope protein of dengue virus type 2. Virology 202 (1994) 885-890
58. Hiramatsu K., Tadano M., Men R., and Lai C.J. Mutational analysis of a neutralization epitope on the dengue type 2 virus (DEN2) envelope protein: monoclonal antibody resistant DEN2/DEN4 chimeras exhibit reduced mouse neurovirulence. Virology 224 (1996) 437-445
59. Lok S.M., Ng M.L., and Aaskov J. Amino acid and phenotypic changes in dengue 2 virus associated with escape from neutralization by IgM antibody. J Med Virol 65 (2001) 315-323
60. Serafin I.L., and Aaskov J. Identification of epitopes on the envelope (E) protein of dengue 2 and dengue 3 viruses using monoclonal antibodies. Arch Virol 146 (2001) 2469-2479
61. Leng C.H., Liu S.J., Tsai J.P., Li Y.S., Chen M.Y., Liu H.H., et al. A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity. Microbes Infect 11 (2009) 288-295
62. Chawla T., Khanna N., and Swaminathan S. Adenovirus vectored vaccines. Expert Opin Ther Patents 18 (2008) 293-307
63. Gaydos C.A., and Gaydos J.C. Adenovirus vaccines. In: Plotkin S.A., and Orenstein W.A. (Eds). Vaccines (1999), WB Saunders Co., Philadelphia 609-628
64. He T.C., Zhou S., DaCosta L.T., Yu J., Kinzler K.W., and Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 95 (1998) 2509-2514
65. Trirawatanapong T., Chandran B., Putnak R., and Padmanabhan R. Mapping of a region of dengue virus type-2 glycoprotein required for binding by a neutralizing monoclonal antibody. Gene 116 (1992) 139-150
66. Kim J.S., Lee S.H., Cho Y.S., Kim Y.H., and Lee J.H. Ectopic expression of the coxsackie virus and adenovirus receptor increases susceptibility to adenoviral infection in the human cervical cancer cell line SiHa. Biochem Biophys Res Commun 288 (2001) 240-244
67. Ebbinghaus C., Al-Jaibaji A., Operschall E., Schöffel A., Peter I., Greber U.F., et al. Functional and selective targeting of adenovirus to high-affinity Fcγ receptor I-positive cells by using a bispecific hybrid adapter. J Virol 75 (2001) 480-489
68. Foxwell B., Browne K., Bondeson J., Clarke C., De Martin R., Brennan F., et al. Efficient adenoviral infection with IκBα reveals that macrophage tumor necrosis factor α production in rheumatoid arthritis is NF-κB dependent. Proc Natl Acad Sci USA 95 (1998) 8211-8215
69. Hombach J., Cardosa M.J., Sabchareon A., Vaughn D.W., and Barrett A.D.T. Scientific consultation on immunological correlates of protection induced by dengue vaccines. Vaccine 25 (2007) 4130-4139
70. Cohen P. Immunity's yin and yang. IAVI Rep 10 (2006) 1-5
71. Shiver J.W., Fu T.M., Chen L., Casimiro D.R., Davies M.E., Evans R.K., et al. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency virus immunity. Nature 415 (2002) 331-335
72. Van Kampen K.R., Shi Z., Gao P., Zhang J., Foster K.W., Chen D.T., et al. Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine 23 (2005) 1029-1036
73. Xiang Z.Q., Yang Y., Wilson J.M., and Ertl H.C.J. A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virology 219 (1996) 220-227
74. Leopold P.L., Wendland R.L., Vincent T., and Crystal R.G. Neutralized adenovirus-immune complexes can mediate effective gene transfer via an Fc receptor-dependent infection pathway. J Virol 80 (2006) 10237-10247
75. Perreau M., Pantaleo G., and Kremer E.J. Activation of dendritic cell-T cell axis by Ad5 immune complexes creates an improved environment for replication of HIV in T cells. J Exp Med 205 (2008) 2717-2725